Revance Therapeutics Reports Surge in Aesthetic Portfolio Growth
Company Announcements

Revance Therapeutics Reports Surge in Aesthetic Portfolio Growth

The latest update is out from Revance Therapeutics (RVNC).

Revance Therapeutics Inc. has reported a significant increase in its aesthetic portfolio, now boasting over 8,000 individual accounts. Impressively, more than 4,200 of these accounts have placed orders for DAXXIFY®, marking a substantial uptick from previous figures released during the second quarter of 2024. This growth highlights the company’s expanding reach in the aesthetics market.

Find detailed analytics on RVNC stock on TipRanks’ Stock Analysis page.

Related Articles
Christine BrownRevance Therapeutics (RVNC) Q3 Earnings Cheat Sheet
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App